Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor-host immune interactions and dendritic cell dysfunction.

Li Yang1, David P Carbone

  • 1Vanderbilt University School of Medicine, Department of Cancer Biology, The Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, USA.

Advances in Cancer Research
|November 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Journal of Cancer·2026
Same author

Dietary and Lifestyle Patterns Among Young Patients with Lung Cancer: Analysis of Mutation-Specific Phenotypes.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Cost-Effectiveness of Perioperative Immune Checkpoint Therapy for NSCLC in Japan, the United States, and Brazil.

JTO clinical and research reports·2026
Same author

Enhanced antitumor efficacy of combined targeting of adenosine A<sub>2B</sub> receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment.

Cancer immunology, immunotherapy : CII·2026
Same author

SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibition.

Science translational medicine·2026
Same journal

Cancer immunotherapy with oncolytic myxoma virus.

Advances in cancer research·2026
Same journal

Cancer terminator viruses: Unique conditionally replication competent oncolytic viruses producing therapeutic anti-cancer immunomodulating agents.

Advances in cancer research·2026
Same journal

Advancing clinical translation of oncolytic adenoviruses.

Advances in cancer research·2026
Same journal

Operation oncolysis: Reoviruses in the theater of cancer war.

Advances in cancer research·2026
Same journal

AAV vectors for cancer gene therapy.

Advances in cancer research·2026
Same journal

Vesicular stomatitis virus (VSV) as an oncolytic therapeutic agent for cancer.

Advances in cancer research·2026
See all related articles

Cancer cells evade immune detection by suppressing immune responses and altering immune cell function. Dendritic cell dysfunction is a key mechanism tumors use to escape immune surveillance and promote tumor growth.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Cancer immunosurveillance, involving natural killer (NK) cells and IFN-gamma, is supported by evidence, yet immune suppression is prevalent in cancer patients.
  • Tumors initially trigger immune responses but down-regulate them, allowing progressive growth through immune escape mechanisms.

Purpose of the Study:

  • To investigate tumor-host immune interactions and the role of dendritic cell (DC) dysfunction in tumor immune evasion.
  • To review findings on tumor immune surveillance, host antitumor responses, and immune system's role in selecting less immunogenic tumor variants.

Main Methods:

  • Review of recent findings on tumor immune surveillance and host antitumor immune responses.
  • Analysis of mechanisms of immune suppression by tumors, including altered DC function and differentiation.

Related Experiment Videos

Main Results:

  • Tumor cells exhibit low MHC class II, costimulatory molecules, and weak antigens, producing immunosuppressive factors (VEGF, IL-10, PGE(2)).
  • Impaired DC differentiation, maturation, migration, and function are critical defects, as DCs are potent antigen-presenting cells (APCs).
  • Tumors induce hematopoiesis, producing immature, directly immunosuppressive DCs.

Conclusions:

  • Dendritic cell dysfunction is a fundamental mechanism by which tumors escape host immune responses.
  • Harnessing the immune system, potentially through DC-based vaccines, offers hope for effective cancer immunotherapy.
  • Understanding tumor-host interactions is crucial for predicting tumor behavior and therapeutic response.